Medication Monitor

Generic Name (Trade Name—Company)
March 1, 2011


(Abilify—Bristol-Myers Squibb)
Indication added for bipolar I disorder


Maintenance treatment of bipolar I disorder as an adjunct to either lithium or valproate

Approval of this agent was based on data from a 52-week maintenance trial with 337 patients with bipolar I disorder. Patients on combination therapy had fewer mood events (n = 25) compared with those on either lithium or valproate alone (n = 43). This difference was primarily attributed to a reduction in manic episodes (7 vs. 19), not depressive episodes (14 vs. 18). Tremor occurred more frequently with combination therapy (6% vs. 2.4%).